Law

The Justice Department announced that dialysis centers agreed to pay $2 million to resolve allegations involving fraud tied to Provider Relief Fund payments. According to the press release, the case centers on alleged misuse of federal pandemic relief funds intended to support healthcare providers. The settlement adds to ongoing federal healthcare-fraud enforcement focused on pandemic-era funding and provider billing compliance.

The Justice Department announced on October 20, 2026 that it reached an agreement with Mount Sinai resolving a federal investigation into the health system’s provision of pediatric gender-related care. The matter is framed as a healthcare enforcement action involving federal legal authority and patient-treatment policy. The agreement appears materially distinct from the previously published law-topic items, which focused on fraud, antitrust, billing, device regulation, and data privacy rather than this type of federal intervention in clinical practice.

This reported investigation examines the legal and practical obstacles patients face when they try to limit or opt out of health-data sharing. It highlights how privacy rights can be difficult to exercise in practice because of fragmented rules, complex consent processes, and limited patient control over downstream data uses. The piece is materially relevant to healthcare law because it centers on the gap between formal privacy protections and real-world enforceability.

The Federal Register publication provides the official legal text of the final Transparency in Coverage rule, CMS-9882-F. As the formal rulemaking document, it sets out the regulatory amendments governing health plan transparency requirements and related implementation details. This source is materially distinct from a fact sheet because it serves as the primary legal publication for compliance and legal analysis.

The Justice Department reported that Signal Diagnostics agreed to pay more than $20 million to resolve False Claims Act allegations tied to the HRSA Uninsured Program. According to the press-release listing, the allegations involved failure to refund overpayments, underscoring that healthcare entities can face major liability not only for initial billing conduct but also for retaining government funds after identifying overpayments. The matter reflects continuing federal attention to pandemic-era reimbursement programs and repayment obligations.

The FDA released a discussion paper and request for feedback on possible regulatory approaches for generative AI-enabled medical devices. The agency is seeking public input on how existing medical device oversight may apply as generative AI features are incorporated into healthcare technologies. This is a notable healthcare law and policy development because it signals active federal consideration of how safety, effectiveness, and post-market oversight should work for AI-enabled devices.

The FDA updated its READI-Home Innovation Challenge page, which focuses on reducing readmissions through device innovation for home use. Although it is less directly legal than fraud or enforcement news, the initiative is relevant to healthcare governance because it shows the agency encouraging device development in an area tied to home-based care and hospital readmission policy. The page also reflects FDA interest in how oversight and innovation intersect in the home-health device space.

CMS announced $8.7 million for ambulance replacement and lifesaving medical equipment upgrades across rural Montana. While not an enforcement action, the announcement is relevant to law and governance because it concerns federal healthcare program implementation and the allocation of public funds for rural emergency medical infrastructure. It offers a window into how the administration is using federal health authorities and funding mechanisms to support rural care capacity.

The Justice Department said a Florida doctor was sentenced for making false statements in connection with a multi-million-dollar healthcare fraud scheme. The announcement describes conduct tied to medically unnecessary genetic testing and durable medical equipment claims, showing continued criminal enforcement against providers linked to fraudulent federal healthcare billing. The case highlights legal exposure not only for submitting false claims, but also for false statements made during the scheme.

The Justice Department announced a $1 million False Claims Act settlement with a skilled nursing company and two executives over allegations that the company billed Medicare and Massachusetts Medicaid for medically unnecessary skilled nursing rehabilitation therapy. According to the announcement, the government alleged the therapy was not reasonable or necessary for certain patients and that resulting claims were improperly submitted for payment. The case adds to federal and state enforcement scrutiny of billing practices in post-acute and long-term care.

An HHS OIG audit posted September 17, 2026 found that Methodist Hospital received at least $12.4 million in Medicare overpayments. The report says the hospital did not fully comply with Medicare billing requirements and recommends that it repay the overpaid amount and strengthen its billing-compliance controls. The findings raise legal and financial risk tied to federal healthcare program billing.

This HHS OIG inspection report, posted September 17, 2026, reviews whether North Carolina’s Medicaid Fraud Control Unit met federal standards for staffing, referrals, fiscal controls, and training. Unlike a fraud case or settlement, it focuses on oversight capacity and compliance infrastructure for investigating Medicaid fraud and patient abuse or neglect. The report is legally significant because it assesses whether a state enforcement unit is operating in line with program requirements.

An HHS OIG report listed on September 16, 2026 concerns Medicare billing compliance at McLeod Regional Medical Center. The audit adds to federal scrutiny of whether hospitals are following Medicare provider billing rules and may expose repayment or corrective-action risk if noncompliance is identified. It is materially different from prior settlement stories because it centers on an audit of provider compliance rather than resolved fraud allegations.

An FDA warning letter posted September 15, 2026 cites sterile-drug current good manufacturing practice violations at Bausch & Lomb’s Tampa facility. The letter signals potential patient-safety concerns and legal exposure if manufacturing deficiencies are not corrected. This is distinct from billing and fraud matters because it involves drug-manufacturing compliance under FDA regulatory authority.

The House-reported text of H.R. 9228, posted on GovInfo on September 15, 2026, addresses access to de-identified health-claims information by ERISA plan fiduciaries. The bill is legally notable because it concerns data access, transparency, and plan oversight rather than fraud enforcement, potentially affecting how employer health plans evaluate costs and administration. Its significance lies in proposed statutory changes, not an agency enforcement action.

The Justice Department announced that an eye practice and its physician owner agreed to pay $350,000 to resolve allegations that they submitted false claims to Medicare. According to the announcement, the matter involves healthcare billing enforcement under the False Claims Act. The case is a smaller but distinct Medicare fraud settlement compared with previously covered large-scale healthcare fraud and kickback matters.

DOJ announced a $541.5 million settlement with The Villages Health System LLC to resolve False Claims Act allegations related to diagnosis coding. The government alleged unsupported diagnoses inflated Medicare Advantage payments, raising compliance and documentation concerns. The settlement is notable for its size and for its implications for coding accuracy, reimbursement oversight, and standards affecting patient care records.

DOJ announced that Veloxis Pharmaceuticals agreed to pay more than $46 million to resolve criminal and civil allegations tied to kickback schemes involving prescriptions for a transplant drug. The resolution centers on alleged unlawful payments and federal healthcare program implications, with DOJ framing the case around program integrity and patient safety. The case underscores continued enforcement against pharmaceutical marketing practices that may influence prescribing.

DOJ announced a nationwide healthcare fraud enforcement action charging 455 defendants in connection with more than $6.5 billion in alleged fraud. The announcement spans schemes involving healthcare fraud, opioid-related conduct, provider exclusions, and allegations of patient harm. It reflects the scale of federal enforcement and the legal risks facing providers, executives, and intermediaries across multiple parts of the healthcare system.

The Justice Department announced a proposed settlement requiring OhioHealth to stop using contract terms alleged to restrict competition. According to DOJ, the challenged terms raised healthcare costs for Ohio patients and employers by limiting insurers' ability to steer patients to lower-cost providers. The matter highlights antitrust scrutiny of healthcare contracting practices with downstream effects on prices and patient choice.

A U.S. Attorney's Office announced a $15.2 million civil judgment resolving Medicaid fraud allegations involving operators of a children's day treatment program. The matter involves behavioral health services for children and includes a corporate integrity agreement and compliance obligations. The resolution highlights legal and oversight risks in pediatric Medicaid-funded care and the importance of program compliance.

DOJ announced that the National Partnership of Insurance Brokers and its former subsidiary agreed to pay more than $135 million to resolve allegations involving an Affordable Care Act enrollment fraud scheme. The case concerns alleged misconduct affecting consumers and federal enrollment processes, with particular relevance to protections for vulnerable enrollees. It illustrates legal exposure for entities involved in insurance marketing and enrollment assistance.